Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Vraylar
|
| gptkbp:activities |
dopamine D3 and D2 receptor partial agonist
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:brand |
gptkb:Vraylar
|
| gptkbp:class |
piperazine derivative
|
| gptkbp:clinical_trial |
Phase III
mood disorders psychotic disorders |
| gptkbp:composed_of |
gptkb:chemical_compound
|
| gptkbp:contraindication |
hypersensitivity to the drug
|
| gptkbp:developed_by |
Gedeon Richter
|
| gptkbp:dosage_form |
oral tablet
|
| gptkbp:duration |
long-term treatment
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
cariprazine
|
| gptkbp:indication |
maintenance treatment of bipolar I disorder
treatment of schizophrenia in adults acute manic or mixed episodes of bipolar I disorder |
| gptkbp:ingredients |
C20 H24 N2 O
|
| gptkbp:interacts_with |
antihypertensives
other antipsychotics CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_available_on |
gptkb:tablet
|
| gptkbp:is_used_for |
schizophrenia
bipolar disorder |
| gptkbp:lifespan |
approximately 2-5 days
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
oral bioavailability
antagonist activity at serotonin receptors |
| gptkbp:research_areas |
mental health
neuroscience psychiatry |
| gptkbp:side_effect |
anxiety
nausea seizures gastrointestinal disturbances restlessness drowsiness insomnia weight gain sedation hyperglycemia extrapyramidal symptoms akathisia neuroleptic malignant syndrome tardive dyskinesia orthostatic hypotension cardiovascular effects |
| gptkbp:type_of |
864812-26-0
|